A randomized double-blind placebo-controlled multicenter trial assessing the impact of lipoprotein(a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Cardiovascular Disease
    Lioprotein (a) Level
  • Age: Between 18 - 80 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Participants must provide written informed consent
    2. Established cardiovascular (CV) disease defined as ANY of the following three conditions:
      • Spontaneous myocardial infarction
      • History of ischemic stroke
      • Clinically significant symptomatic peripheral artery disease

You may not be eligible for this study if the following are true:

    1. Uncontrolled hypertension
    2. Treatment with niacin = 2000 mg (2 g) daily in the 3 months before
    3. Had myocardial infarction, stroke, coronary or lower limb re-vascularization, major cardiac or non-cardiac surgery within 3 months of screening
    4. Heart failure New York Heart Association (NYHA) class IV
    5. History of hemorrhagic stroke or other major bleeding
    6. Severe concomitant non-CV disease that is expected to reduce life expectancy to less than 5 years
    7. Known active severe infection or major hematologic, metabolic, gastrointestinal or endocrine dysfunction
    8. History of malignancy of any organ system
    9. Active liver disease or hepatic dysfunction
    10. Positive HIV, Hepatitis C screening or Hepatitis B Surface Antigen tests
    11. Any other conditions which in the opinion of the Investigator would make the patient unsuitable for inclusion, or could interfere with the patient participating in or completing the study
    12. Pregnant or lactating
    13. Unwillingness or inability (e.g. physical or cognitive) to comply with study procedures and medication administration (injections) and schedule

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.